Filing Details
- Accession Number:
- 0001104659-24-128559
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-12-13 20:01:11
- Reporting Period:
- 2024-12-11
- Accepted Time:
- 2024-12-13 20:01:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1974640 | Apogee Therapeutics Inc. | APGE | Biological Products, (No Disgnostic Substances) (2836) | 934958665 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1983476 | Carl Dambkowski | C/O Apogee Therapeutics, Inc. 221 Crescent St., Bldg. 17, Ste. 102B Waltham MA 02453 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-12-11 | 1,815 | $22.86 | 262,613 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-12-11 | 4,085 | $48.62 | 258,528 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-12-11 | 455 | $50.00 | 258,073 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-12-11 | 1,815 | $0.00 | 1,815 | $22.86 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 173,530 | 2033-12-18 | No | 4 | M | Direct |
Footnotes
- This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.
- This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.
Billionaire Hedge Funds
